

Greg Mann



Greg Mann is a Senior Expert in Science & Technology in the Biocatalysis team within Chemical and Analytical Development at Novartis. In 2016, Greg obtained a PhD in Biochemistry from the University of St Andrews (Scotland, UK), where he developed a chemoenzymatic synthesis of diverse, highly modified, cyclic peptides. He then moved to EPFL as a postdoctoral researcher where he worked in the field of therapeutic protein engineering and developed monobodies as potent biotherapeutics against notorious oncoproteins. In 2019, Greg joined the Biocatalysis team at Novartis as a molecular biologist and contributes to the high throughput evolution of enzymes for implementation in biocatalytic synthetic processes. During this time, Greg has managed several evolution projects and spearheaded efforts to investigate next generation biocatalytic synthesis of xRNA. In addition to his role, Greg leads the academic network, serving as the link between academia and industry within Chemical and Analytical Development.